Otsuka Pharmaceutical submits NDA for voclosporin in Japan
Otsuka Pharmaceutical has submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for voclosporin to treat lupus nephritis (LN).
Page 3 - Peter Greenleaf News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Greenleaf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Greenleaf Today - Breaking & Trending Today
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
ROCKVILLE, Md. & EDMONTON, Alberta, November 13, 2023--Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
Source: yahoo.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript
Operator: Greetings. Welcome to Aurinia Pharmaceuticals Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Source: insidermonkey.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2023 Earnings Call Transcript
Operator: Greetings. And welcome to Aurinia Pharmaceuticals Incorporated Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Source: insidermonkey.com
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
03.08.2023 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023. Amounts are expressed in U.S. dollars. Total net revenue was $41.5 million for the three months ...
Source: wallstreet-online.de